Delcath Systems (DCTH) vs Hyperfine (HYPR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Delcath Systems (DCTH) has outperformed Hyperfine (HYPR) over the past year, gaining 35.5% versus a loss of 55.0%. Over five years, DCTH leads with a +59.8% price change compared with -90.5% for HYPR. Delcath Systems is the larger company by market cap ($523.6 million vs $101.9 million), about 5.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DCTH | HYPR |
|---|---|---|
| Share price | $15.09 | $0.961 |
| Market cap | $523.60M | $101.91M |
| 1-day change | +0.33% | +2.22% |
| YTD return | +48.91% | -3.97% |
| 1-year return | +35.50% | -55.02% |
| 5-year return | +59.83% | -90.54% |
| Forward P/E | 335.33 | — |
| EPS (TTM) | $0.01 | $-0.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.42 | $2.22 |
| 52-week low | $8.12 | $0.754 |
| Distance from 52-week high | -13.38% | -56.71% |
| Analyst consensus | none | none |
| Avg. price target upside | +59.05% | +111.24% |
| Average volume | 479.73K | 765.15K |
| Shares outstanding | 34.70M | 90.99M |
| Employees | 156 | 102 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Delcath Systems is about 5.1 times larger than Hyperfine by market value ($523.60M vs $101.91M).
- DCTH has outperformed HYPR by 90.5 percentage points over the past year.
About Delcath Systems
DCTH stock →Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Health Care · Medical/Dental Instruments · 156 employees
About Hyperfine
HYPR stock →Hyperfine, Inc., a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products. Its Swoop Portable MR Imaging System produces images at a lower magnetic field strength than conventional MRI scanners.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 102 employees
DCTH vs HYPR FAQ
Which is bigger, Delcath Systems or Hyperfine?
Delcath Systems (DCTH) is larger, with a market capitalization of $523.60M compared with $101.91M for Hyperfine (HYPR).
Which stock has performed better over the past year, DCTH or HYPR?
DCTH returned +35.50% over the past 12 months, compared with -55.02% for HYPR (price return, excluding dividends). Past performance does not predict future results.
Are Delcath Systems and Hyperfine in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for Delcath Systems and Biotechnology: Electromedical & Electrotherapeutic Apparatus for Hyperfine.